Cargando…
Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
INTRODUCTION: Uncommon epidermal growth factor receptor (EGFR) mutations include single and complex mutations. However, the association of the smoking status of patients with uncommon and complex EGFR mutations remains unclear. METHODS: This retrospective study evaluates the spectrum of uncommon EGF...
Autores principales: | Ko, How-Wen, Shie, Shian-Sen, Wang, Chih-Wei, Chiu, Chi-Tsun, Wang, Chih-Liang, Yang, Tsung-Ying, Chou, Shou-Chu, Liu, Chien-Ying, Kuo, Chih-Hsi Scott, Lin, Yu-Ching, Li, Li-Fu, Yang, Cheng-Ta, Wang, Chin-Chou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632177/ https://www.ncbi.nlm.nih.gov/pubmed/36341427 http://dx.doi.org/10.3389/fimmu.2022.1011092 |
Ejemplares similares
-
Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab
por: Ko, How-Wen, et al.
Publicado: (2022) -
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
por: Liu, Chien-Ying, et al.
Publicado: (2017) -
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon
EGFR
mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022) -
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions
por: Hsu, Ping-Chih, et al.
Publicado: (2016) -
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
por: Tsai, Ming-Ju, et al.
Publicado: (2018)